2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)


Published on

by Ilene Ruhoy

This slidecast is part of the GreenPharmEdu.org program

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)

  1. 1. Significance of Long-Term Exposure to Multiple APIs <br />
  2. 2. Toxicity of Complex Environmental Mixtures:Major Unanswered Questions<br />?<br />What is the significance of long-term exposure to multiple APIs each presentat levels below known effect levels?<br />
  3. 3. The Potential forHuman Health Effects<br />Human exposure to APIs recycled from the environment via potable water is limited.<br />Extremely low concentrations (< 10 ng/L)<br />Many APIs insource waters are removed by treatment<br />Toxicological research restricted to in vitro studies and very limited epidemiological data.<br />Concern focused primarily on vulnerable windows of exposure (e.g., fetal exposure) or to contraindicated APIs.<br />Comparisons made with therapeutic levels are irrelevant (different mechanisms of action at ultra-low levels)<br />
  4. 4. Human Exposure<br />Function of<br />Identities, quantities, & geographic distribution of APIs<br />ADME<br />Environmental transport<br />Environmental fate<br />Exposure routes<br />
  5. 5. Key Questions<br />Despite the years of debate and discussion, surprisingly no single, comprehensive resource exists that examines and distills what is known (and what further needs to be known) and that provides a synoptic overview of this multi-faceted topic.<br />Key questions<br />Where do leftover drugs accumulate in society?<br />What causes their accumulation?<br />What are the routes and methods used in their disposal?<br />What portion of drug residues in the environment originate from disposal?<br />What are the risks for humans, domestic animals, and wildlife?<br />How can the accumulation of excess medications by consumers be minimized or eliminated?<br />How can these unwanted drugs be best disposed?<br />Are there potential benefits beyond reduced environmental impact by minimizing the incidence of leftover medications?<br />
  6. 6. Tying Effects to Exposure<br />Considerable evidence exists on the potential for low-dose effects from cellular and whole-organisms controlled exposures at levels lower than the nm or even pm ranges.<br />But identifying and trying adverse consequences in non-target organisms exposed in real-world settings has met with limited success.<br />To what extent do morphological abnormalities in aquatic organisms result from trace-level anthropogenic chemical exposures versus natural incidence?<br />Similarly: to what extent can biological effects be maskedor concealed by ambient incident?<br />
  7. 7. Tying Effects to Exposure<br />Subtle effects, such as behavioral or immunological, can result from chronic low-level exposures from single or multiple PPCPs, each present below purported no-observed effects levels<br />Such receptors sometimes involve receptors that differ than those in humans<br />Mechanisms of actions (MOAs) can change as the exposure levels are reduced, and dose-response linearity can vary greatly among chemicals<br />Furthermore, actual MOAs are frequently unknown and individual APIs can be promiscuous in their biochemical actions<br />
  8. 8. Environmental Residues<br />APIs enter the environment by three primary routes:<br />Excretion (primarily via urine and secondarily via feces) comprises continual low-level contributions from multitudes of people<br />Bathingreleases APIs from medications applied directly to the skin and excreted via sweat *<br />Disposalof leftover, unwanted medications represents acute but transient and episodic contributions from fewer people<br />Disposalis the best route for pollution prevention / source control measures<br /><ul><li>Indirect entry can occur via disposal of unwanted drugs and used delivery devices to trash (e.g., in leachates from landfills)
  9. 9. Proper disposal is greatly complicated by the conflict between the need to protect public safety (e.g., from drug diversion) and the need to minimize environmental exposure</li></ul>* DaughtonCG and Ruhoy IS. "Environmental Footprint of Pharmaceuticals: The Significance of Factors Beyond Direct Excretion to Sewers," Environmental Toxicology & Chemistry 2009, 28(12):2495-2521; doi:10.1897/08-382.1; available: http://www3.interscience.wiley.com/cgi-bin/fulltext/123234136/PDFSTART<br />
  10. 10. Sewage Treatment &<br />Natural Attenuation <br /><ul><li>Efficiency of API removal is highly variable – ranging from nearly complete to almost nil as a function of the API.
  11. 11. Concentrations in treated sewage often range from 1-100 ng/L.
  12. 12. “Removal” does not necessarily equate with “destruction” or with elimination of toxicity.
  13. 13. Parent (unchanged) APIs can partition to solid sludge (biosolids).
  14. 14. Bioactive transformation products can be created.
  15. 15. API conjugates serve as hidden reservoirs of parent API.</li></li></ul><li>Environmental Pollution<br />Water treatment<br />Minimal or no treatmentSeptic systems, straight-piping, storm over-flow<br />ConventionalCoagulation, flocculation, depth filtration<br />AdvancedChlorination, Ozonation, activated carbon, reverse osmosis, nanofiltration<br />Some APIs are still refractory<br />Examples: Carbamazepine, ibuprofen, clofibric acid, 17α-ethinylestradiol, meprobamate, dilantin, contrast agents, chemotherapeutics, some β-blockers<br />Not just parent APIs: some metabolites, degradates, and transformation products can be more mobile, more persistent, and potentially as toxic<br />